Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) News
Filter ENZ News Items
ENZ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ENZ News From Around the Web
Below are the latest news stories about ENZO BIOCHEM INC that investors may wish to consider to help them evaluate ENZ as an investment opportunity.
Enzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Call TranscriptEnzo Biochem, Inc. (NYSE:ENZ) Q1 2023 Earnings Call Transcript December 13, 2022 Operator: Greetings and welcome to the Enzo Biochem, Incorporated First Quarter 2023 Earnings Call. At this all participants are in a listen-only mode. . Please note that this conference is being recorded. At this time I will turn the conference over to Brendan […] |
Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update- Enzo Life Sciences reports revenue of $7.1 million and 9% growth in Q1 FY 2023, excluding FX - Engagement with investment bank to provide advisory services including the evaluation of strategic alternatives for the Company is progressing well. - Continuing to make progress in market expansion of the current product portfolio, commercialization of the Company’s offerings, and optimization of the clinical service segment. Conference call and live webcast scheduled for tomorrow, Tuesday, December |
Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12thConference Call and Webcast Scheduled for December 13th, 8:30 AM ET New York, NY, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022. The Form 10-Q filing will be followed by a live audio webcast and conference call the next day at 8:30 AM ET. To participate in the conference call, please dia |
As Enzo Biochem, Inc. (NYSE:ENZ) drops to US$100m market cap, insiders might rethink their US$3.1m stock purchase earlier this yearThe recent 13% drop in Enzo Biochem, Inc.'s ( NYSE:ENZ ) stock could come as a blow to insiders who purchased US$3.1m... |
Enzo Biochem, Inc. Announces Date of Annual Shareholders’ MeetingNEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders’ Meeting will be held on January 31, 2023. Shareholders must submit proposals and/or director nominations in connection with meeting no later than November 18, 2022 to be considered timely. About Enzo Biochem Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical labor |
Farmer Bros. Co. Announces Board Refresh and Cooperation Agreement with Stockholders JCP Investment Management and 22NWNORTHLAKE, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Farmer Bros. Co. (NASDAQ: FARM) (the “Company”), today announced it has entered into a cooperation agreement (the “Cooperation Agreement”) with JCP Investment Management, LLC (collectively with its affiliates, “JCP”) and 22NW, LP (collectively with its affiliates, “22NW”), which together own approximately 15.7% of the Company’s outstanding common stock. Under the Cooperation Agreement, the Company has agreed to promptly appoint Bradley L. Radof |
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO- David Bench resigning to pursue a new career opportunity -NEW YORK, NY, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. Eckert’s appointment follows the resignation of David Bench, who is departing the Company effective November 14, 2022 to pursue a new opportunity. “While bittersweet in light of David’ |
The past five years for Enzo Biochem (NYSE:ENZ) investors has not been profitableLong term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic... |
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company successfully launched AMPIVIEW™ gene expression platform powered by LoopRNA™ ISH technology - Continues to engage with previously announced investment bank to provide advisory services including the evaluation of strategic alternatives for the Company - Under the leadership of a new CEO, Enzo has been reorganized to leverage on our ‘focused return’ strategy including the appointment of new executi |
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14thConference Call and Webcast Scheduled for October 14, 2022, 8:30 am ET NEW YORK, NY, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket. The announcement will be followed by a live audio webcast and conference call the same day at 8:30 am Eastern Time. Please see additional details below: Friday, October 14th @ 8:30 am ETDom |